Sensorion (FRA:RFM) Stock Based Compensation: €1.63 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RFM Sensorion SA FRA:RFM
17 GF Score
Price €0.23
! 1 Warning Sign
View Full Analysis

What is Sensorion Stock Based Compensation?

Sensorion FRA:RFM -1.74% 17 Stock Based Compensation is €1.63 Mil as of Dec. 2025. GuruFocus rates FRA:RFM with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Sensorion's Stock Based Compensation for the six months ended in Dec. 2025 was €0.84 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €1.63 Mil.

Sensorion Stock Based Compensation Related Terms

Sensorion Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Sensorion's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensorion Stock Based Compensation Chart

Sensorion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 1.12 0.30 1.02 1.63

Sensorion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.39 0.63 0.78 0.84
FRA:RFM
17GF Score
Sensorion SA FRA:RFM
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensorion Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.63 Mil.

What does a Stock Based Compensation of €1.63 Mil mean?
Sensorion (FRA:RFM) has a Stock Based Compensation of €1.63 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sensorion and its competitors.
Is Sensorion's Stock Based Compensation too high?
Sensorion's current Stock Based Compensation is €1.63 Mil. Overall, Sensorion has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's Stock Based Compensation compare to VRTX and REGN?
Sensorion's Stock Based Compensation of €1.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sensorion and its competitors. Sensorion's current Stock Based Compensation is €1.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (FRA:RFM) has a current Stock Based Compensation of €1.63 Mil. The current Stock Based Compensation is €1.63 Mil. Sensorion's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Sensorion (FRA:RFM), the current Stock Based Compensation is €1.63 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sensorion Business Description

Other Exchanges ALSEN:FranceRFM:Germany
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
17GF Score

Get the complete analysis for FRA:RFM

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price